William Berry to Antineoplastic Agents
This is a "connection" page, showing publications William Berry has written about Antineoplastic Agents.
Connection Strength
0.213
-
Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Int J Cancer. 2017 05 15; 140(10):2331-2343.
Score: 0.093
-
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 06; 13:103.
Score: 0.076
-
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
Score: 0.025
-
Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One. 2013; 8(11):e80304.
Score: 0.019